myelin-basic-protein and Carcinoma-in-Situ

We applied the electrophoretic mobility test (EMT) to 117 patients. 49 patients suffered from gynecological malignant tumors of different types and eleven had a carcinoma in situ. 57 patients served as a control group, 26 of whom were clinically healthy volunteers and 31 had benign gynecological diseases. In the EMT all malignant cases had inhibition values of at least-5% or even more. All other tested persons, the so-called non-malignant or healthy cases, had an inhibition of less than -5% or even an acceleration of the tanned sheep erythrocytes stabilized with sulfosalicylic acid (ETS).

Topics: Antigens; Carcinoma in Situ; Cell Migration Inhibition; Electrophoresis; Erythrocytes; Female; Genital Neoplasms, Female; Humans; Lymphocytes; Myelin Basic Protein

Sensitization to human myelin basic protein or encephalitogenic factor (EF), and antigen thought to be analogous to different human tumours, can be measured by the macrophage migration inhibition test (MMI). The MMI test was done on one occasion in 51 women with dysplasia and carcinoma in situ of the cervix; 20 women with non-malignant gynaecological conditions served as controls. Sensitization to EF was found in 71 per cent of women with carcinoma in situ and 42 per cent of women with dysplasia. None of the controls showed sensitization. Sensitization could not be related to histological evidence for cellular infiltration within the cervix.

Topics: Adult; Carcinoma in Situ; Cell Migration Inhibition; Cervix Uteri; Female; Humans; Immunity, Cellular; Macrophages; Middle Aged; Myelin Basic Protein; Precancerous Conditions; Uterine Cervical Neoplasms